$6 billion acquisition! Medical giant Bausch Health plans to take a controlling stake in Surgery Partners (SGRY.US)
Boston Consulting Group plans to acquire a controlling stake in Surgery Partners for approximately $6 billions, at $20 per share; Bain Capital will retain a 40% stake, and the deal could be announced as early as Monday.
According to sources cited by Zhihui Caijing APP, Bon Secours Mercy Health is in late-stage negotiations to acquire a majority stake in surgery services provider Surgery Partners (SGRY.US). This transaction would value the Bain Capital-backed company at approximately $6 billion, including $3.5 billion in debt.
Bon Secours’ partial acquisition of Surgery Partners would value the company at about $20 per share. Bain Capital will retain its nearly 40% stake.
After over a year of efforts to find a buyer for Surgery Partners, this potential deal could be announced as early as Monday. Previously, Bain Capital abandoned a deal with an enterprise value of $6.7 billion.
Bon Secours operates 47 hospitals and generated about $14 billion in revenue last year. Surgery Partners operates 176 surgery centers and hospitals across 30 U.S. states.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Korean retail investors start bottom fishing! Their targets are still "Samsung and SK Hynix leveraged ETFs"
Amid a sharp drop in Korean stocks, Korean retail investors turned contrarian, making a net purchase of over 315.4 billion KRW in leveraged products of Samsung and SK Hynix in October alone. They simultaneously spent 4.7 trillion KRW acquiring US-listed triple-leveraged semiconductor ETF (SOXL), accounting for nearly 74% of total purchases of US stocks during the same period. This marks the first rebound since tightening regulations in July and two consecutive months of net selling.
AI Bubble Index at 74, CoreWeave (CRWV.US) stock price may fall below $50
CoreWeave's stock price has dropped nearly 70% from its peak to $54.25, with the short interest ratio rising to 15%. As the AI bubble index reaches an extreme value of 74 and the company faces $3 billion in debt pressure, its share price is at risk of falling below the critical support level of $50.
Cramer Beat the S&P At His Hedge Fund But Advises Retail to Join The Index
Trump Calls Off Iran Strike But Will Oil Hold Above $100?
Crypto prices
More
